Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 13% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Nurix (NRIX) PT Raised to $34 at Stifel
October 14, 2024 8:33 AM EDT(Updated - October 14, 2024 8:34 AM EDT)
Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst commented: "We like implied risk/reward into the anticipated update of P1/1b NX-5948 data... More
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
October 14, 2024 7:36 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX reported 3Q24 earnings and provided a pipeline update. Most importantly, development of NX-5948 remains on track with two Phase Ia updates expected... More
Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
October 14, 2024 3:50 AM EDTNurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.
For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.
... MoreJefferies Starts Nurix (NRIX) at Buy
October 11, 2024 5:25 AM EDTJefferies analyst Roger Song initiates coverage on Nurix (NASDAQ: NRIX) with a Buy rating and a price target of $41.00.
The analyst said: "NRIX focuses on targeted protein modulation for cancer and I&I. Lead '5948 (BTK degrader) aims to better address broad BTK... More
